AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (NVBU)
Live price chart, market sentiment, and community perspectives for AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (CBOE: NVBU).
Live price chart, market sentiment, and community perspectives for AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (CBOE: NVBU).
On our desk, monitoring the liquidity profile of NVBU has been critical. With daily volume frequently residing around a few thousand shares or lower—such as recent volume prints near 317 to 5,200 shares—and assets under management fluctuating between $34 million and $44 million, execution requires careful limit ordering to avoid wide bid-ask spreads, which recently showed a 30-day median bid-ask spread of 0.26%.
In our discussions regarding niche ETF products, AllianzIM’s uncapped November series (NVBU) attracts interest primarily from wealth managers seeking to systematically clip tail risk without sacrificing all participation in SandP 500 gains. Even so, the relatively modest AUM means secondary market liquidity is thin compared to massive plain-vanilla index funds.
Looking at the market sentiment and valuation structure, retail and quantitative models evaluate NVBU as a specialized tool for risk-averse allocators. Danelfin's AI-powered analysis places it low on the scoring matrix relative to broader equity ETFs, reflecting a niche appeal for investors prioritizing the 15% buffer feature over pure index replication or aggressive growth mandates.
From a risk management standpoint, Morningstar metrics show the fund operates with a low standard deviation and beta relative to broader categories, aligning with its conservative-to-moderate risk footprint. However, analysts must weigh the 0.74% expense ratio against potential upside limitations or tracking variations inherent to structured buffer ETFs utilizing options combinations.
During our options desk review, we map out the exact parameters reported for NVBU, noting its inception on October 31, 2024, and its structural reliance on specific SPY-linked option prices set at the beginning of each outcome period. Analysts must verify the prevailing NAV ($30.53 as of June 2026) versus closing market prices to capture any persistent premiums or discounts.
Explore plasma cleansing, somatic organ swaps, and BCI.